


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-93. (Cancelled)

94. (Currently Amended) An ANT ligand having the following structure:



and stereoisomers and pharmaceutically acceptable salts thereof,

wherein

R₁ is ~~hydroxyl~~, halogen, -OC(=O)R₄ or -NHR₄;

R₂ is hydrogen or -C(=O)R₅;

R₃ is -CH₃ or =CH₂;

R₄ is ~~-X-aryl~~, ~~-X-substituted-aryl~~, -X-arylalkyl, -X-substituted
arylalkyl, X-heteroaryl, or -X-heteroarylalkyl, wherein X is an optional amido or alkylamido
linker moiety; and

R₅ is alkyl.

95. (Cancelled)

96. (Currently Amended) The ANT ligand of claim 94 wherein R_1 is $-\underline{O}C(=O)R_4$.

97. (Original) The ANT ligand of claim 94 wherein R_1 is $-NHR_4$.

98. (Original) The ANT ligand of claim 94 wherein R_2 is hydrogen.

99. (Original) The ANT ligand of claim 94 wherein R_2 is $-C(=O)R_5$.

100. (Original) The ANT ligand of claim 94 wherein R_3 is $-\text{CH}_3$.

101. (Original) The ANT ligand of claim 94 wherein R_3 is $=\text{CH}_2$.

102. (Currently Amended) The ANT ligand of claim 94 wherein R_4 is $-\text{X-aryl}$, ~~$-\text{X-substituted aryl}$~~ , $-\text{X-arylalkyl}$ or $-\text{X-substituted arylalkyl}$.

103-107. (Cancelled)

108. (Original) A pharmaceutical composition comprising an ANT ligand of claim 94.

109-112. (Cancelled)